Souhaitez-vous accéder aux communiqués récents ?

- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO...

BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are...

Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors...

Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

Italy marked a significant presence at PDAC 2026, the world’s premier mining & exploration convention, showcasing the height of "Made in Italy" technology.

Immuneering to Present at the Leerink Global Healthcare Conference

Jim Coates appointment full-time permanent CEO

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million. Reference is made to the stock exchange announcement published on 27 January 2026...

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Janu